17692-31-8 | 3-(4-phenylpiperazin-1-yl)propane-1,2-diol

Packsize	Purity	Availability	Price	Discounted Price
25mg	98% NMR	in stock	$6.00	$4.00
100mg	98% NMR	in stock	$7.00	$5.00
1g	98% NMR	in stock	$10.00	$7.00
5g	98% NMR	in stock	$17.00	$12.00
25g	98% NMR	in stock	$27.00	$19.00
100g	98% NMR	in stock	$92.00	$65.00
500g	98% NMR	in stock	$334.00	$234.00

Description

• Catalog Number: AA99580
• Chemical Name: 3-(4-phenylpiperazin-1-yl)propane-1,2-diol
• CAS Number: 17692-31-8
• Molecular Formula: C13H20N2O2
• Molecular Weight: 236.3101
• MDL Number: MFCD00079124
• SMILES: OCC(CN1CCN(CC1)c1ccccc1)O
• NSC Number: 757820

Computed Properties

• Complexity: 212
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 17
• Hydrogen Bond Acceptor Count: 4
• Hydrogen Bond Donor Count: 2
• Rotatable Bond Count: 4
• Undefined Atom Stereocenter Count: 1
• XLogP3: 0.6

Literature

• Effects of four antitussives on airway neurogenic inflammation in a guinea pig model of chronic cough induced by cigarette smoke exposure.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20131201

• Efficacy of levodropropizine in pediatric cough.

  Pulmonary pharmacology & therapeutics 20121001

• Levodropropizine in the management of cough associated with cancer or nonmalignant chronic disease--a systematic review.

  Journal of pain & palliative care pharmacotherapy 20110101

• Cough management: a practical approach.

  Cough (London, England) 20110101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• An anaphylactic reaction caused by levodropropizine.

  Allergy 20100301

• Sensitive spectrophotometric method for quantitation of guaifenesin and dropropizine in their dosage forms.

  International journal of analytical chemistry 20100101

• The influence of animal species on the relationship between ATP-sensitive potassium ion channels and defense reflexes of the airways.

  Bratislavske lekarske listy 20090101

• HPLC determination and steady-state bioavailability study of levodropropizine sustained-release tablets in dogs.

  Archives of pharmacal research 20060601

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Rapid and sensitive liquid chromatography-tandem mass spectrometry method for the quantitation of levodropropizine in human plasma.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20050505

• [Determination of levodropropizine and its pharmacokinetics in human plasma using LC/MS/MS].

  Yao xue xue bao = Acta pharmaceutica Sinica 20041201

• Studies on the human metabolism and the toxicologic detection of the cough suppressant dropropizine in urine using gas chromatography-mass spectrometry.

  Therapeutic drug monitoring 20040801

• Antitussive effect of diltiazem in experimental conditions.

  Bratislavske lekarske listy 20040101

• Levocloperastine in the treatment of chronic nonproductive cough: comparative efficacy versus standard antitussive agents.

  Drugs under experimental and clinical research 20040101

• Toxicological detection of the new designer drug 1-(4-methoxyphenyl)piperazine and its metabolites in urine and differentiation from an intake of structurally related medicaments using gas chromatography-mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031225

• Chemo-enzymatic synthesis of levodropropizine.

  Farmaco (Societa chimica italiana : 1989) 20031001

• Levodropropizine does not affect P0.1 and breathing pattern in healthy volunteers and patients with chronic respiratory impairment.

  Pulmonary pharmacology & therapeutics 20030101

• Antitussive activity of the fruit extract of Emblica officinalis Gaertn. (Euphorbiaceae).

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20030101